BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) and Metagenomi (NASDAQ:MGX – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.
Profitability
This table compares BioMarin Pharmaceutical and Metagenomi’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioMarin Pharmaceutical | 2.14% | 5.32% | 3.69% |
| Metagenomi | -384.61% | -63.65% | -44.52% |
Analyst Recommendations
This is a breakdown of current ratings for BioMarin Pharmaceutical and Metagenomi, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioMarin Pharmaceutical | 1 | 6 | 15 | 1 | 2.70 |
| Metagenomi | 1 | 0 | 2 | 1 | 2.75 |
Risk & Volatility
BioMarin Pharmaceutical has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500. Comparatively, Metagenomi has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500.
Insider & Institutional Ownership
98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by company insiders. Comparatively, 12.5% of Metagenomi shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares BioMarin Pharmaceutical and Metagenomi”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioMarin Pharmaceutical | $3.41 billion | 3.42 | $348.90 million | $0.37 | 162.86 |
| Metagenomi | $13.56 million | 3.20 | -$87.87 million | ($2.49) | -0.46 |
BioMarin Pharmaceutical has higher revenue and earnings than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Summary
BioMarin Pharmaceutical beats Metagenomi on 10 of the 14 factors compared between the two stocks.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.
About Metagenomi
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
